Jeffrey Cislini serves as General Counsel and Secretary at Revolution Medicines Inc., a clinical-stage oncology company pioneering novel RAS(ON) inhibitors and other targeted therapies to address unmet needs in cancer treatment. In this critical role since joining the company in 2019, Cislini oversees all legal functions, including corporate governance, intellectual property strategy, regulatory compliance, mergers and acquisitions, and strategic partnerships. He has been instrumental in supporting the company's expansion, including multiple equity financings raising over $1 billion, key collaborations such as the alliance with Sanofi, and advancement of pipeline assets like RMC-6236 into late-stage clinical trials. Prior to Revolution Medicines, Cislini built a distinguished career in life sciences law at leading biotechnology firms. As Vice President, General Counsel, and Secretary at Nektar Therapeutics from 2015 to 2019, he navigated complex clinical development programs, licensing agreements, and litigation matters during a transformative period for the company. Earlier, he held roles as Associate General Counsel at Onyx Pharmaceuticals (acquired by Amgen in 2013), where he contributed to blockbuster drug launches like Kyprolis and major IP protections, and at Genentech, honing his expertise in biotech regulatory and transactional law. A seasoned legal advisor with deep biotech industry knowledge, Cislini earned his J.D. from the University of San Francisco School of Law and his B.A. from the University of California, Berkeley. His achievements include structuring high-stakes deals that have accelerated innovation in oncology and maintaining a spotless record of compliance in a highly regulated sector, earning him recognition among peers for his strategic foresight and collaborative leadership.